Paper8298
[Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].
Kaltenbach M and 2 others. Dtsch Med Wochenschr, 1976. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. [Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)]. Papers, record 8298. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8298
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- [Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)].
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calcium | Major topic |
| Cardiomyopathy, Hypertrophic | Major topic |
| Verapamil | Major topic |
| Adrenergic beta-Antagonists | |
| Adult | |
| Cardiac Volume | |
| Drug Evaluation | |
| Electrocardiography | |
| Female | |
| Humans | |
| Long-Term Care | |
| Male | |
| Middle Aged |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34948439 | Mass-Spectrometry-Based Functional Proteomic and Phosphoproteomic Technologies and Their Application for Analyzing Ex Vivo and In Vitro Models of Hypertrophic Cardiomyopathy. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34948439 | PubMed |
| 7202472 | Superiority of stable isotope techniques in the assessment of the bioavailability of drugs undergoing extensive first pass elimination. Studies of the relative bioavailability of verapamil tablets. | Eur J Clin Pharmacol | 1981 | https://conductscience.org/library/papers/7202472 | PubMed |
| 7023517 | Role of calcium antagonists in cardiovascular therapy. | Br Heart J | 1981 | https://conductscience.org/library/papers/7023517 | PubMed |
| 7018425 | Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation. | Ann Surg | 1981 | https://conductscience.org/library/papers/7018425 | PubMed |
| 6714292 | Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing. Studies with deuterated verapamil. | Eur J Clin Pharmacol | 1984 | https://conductscience.org/library/papers/6714292 | PubMed |
| 2408698 | Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. | Br J Pharmacol | 1985 | https://conductscience.org/library/papers/2408698 | PubMed |
| 1999483 | Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole. | J Clin Invest | 1991 | https://conductscience.org/library/papers/1999483 | PubMed |
| 573129 | Treatment of hypertrophic obstructive cardiomyopathy with verapamil. | Br Heart J | 1979 | https://conductscience.org/library/papers/573129 | PubMed |
| 375589 | Nonobstructive and obstructive hypertrophic cardiomyopathies. | West J Med | 1979 | https://conductscience.org/library/papers/375589 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8298
GET https://conductscience.org/api/papers/v1/8298/authors